Literature DB >> 12905016

Immunogenicity of recombinant BCG vaccine strains overexpressing components of the antigen 85 complex of Mycobacterium tuberculosis.

Neeraj Dhar1, Vivek Rao, Anil K Tyagi.   

Abstract

The components of antigen 85 complex of Mycobacterium tuberculosis (Ag 85A, Ag 85B and Ag 85C), due to their immunodominant and secretory nature, represent promising protective antigen candidates and have been used in numerous vaccine preparations. We have used recombinant Bacille Calmette Guerin (BCG) strains overexpressing Ag 85A and Ag 85C to immunize BALB/c mice to investigate the immunogenicity of these strains. Mice immunized with recombinant BCG strains exhibited an increased humoral immune response when compared to mice immunized with wild-type BCG. The recombinant BCG strain overexpressing Ag 85A also induced an increased Th1-like response, characterized by elevated levels of IFN-gamma in antigen stimulated splenocyte cultures and a strong IgG2a antibody response, when compared to wild-type BCG. Immunization with recombinant BCG strain overexpressing Ag 85C, on the other hand did not elicit increased IFN-gamma secretion on restimulation of splenocytes in vitro.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12905016     DOI： 10.1007/s00430-002-0170-x

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN： 0300-8584            Impact factor:   3.402


  20 in total

Review 1.  TB vaccines: progress and problems.

Authors:  P Andersen
Journal:  Trends Immunol       Date:  2001-03       Impact factor: 16.687

Review 2.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

3.  Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis.

Authors:  J T Belisle; V D Vissa; T Sievert; K Takayama; P J Brennan; G S Besra
Journal:  Science       Date:  1997-05-30       Impact factor: 47.728

4.  Inhibition of multiplication of Mycobacterium leprae in mouse foot pads by recombinant Bacillus Catmette-Guérin (BCG).

Authors:  N Ohara; M Matsuoka; H Nomaguchi; M Naito; T Yamada
Journal:  Vaccine       Date:  2000-01-31       Impact factor: 3.641

5.  Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex.

Authors:  E Lozes; K Huygen; J Content; O Denis; D L Montgomery; A M Yawman; P Vandenbussche; J P Van Vooren; A Drowart; J B Ulmer; M A Liu
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

6.  Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis.

Authors:  A T Kamath; C G Feng; M Macdonald; H Briscoe; W J Britton
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

7.  Immunogenicity and protective efficacy of a tuberculosis DNA vaccine.

Authors:  K Huygen; J Content; O Denis; D L Montgomery; A M Yawman; R R Deck; C M DeWitt; I M Orme; S Baldwin; C D'Souza; A Drowart; E Lozes; P Vandenbussche; J P Van Vooren; M A Liu; J B Ulmer
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

8.  Recombinant BCG approach for development of vaccines: cloning and expression of immunodominant antigens of M. tuberculosis.

Authors:  N Dhar; V Rao; A K Tyagi
Journal:  FEMS Microbiol Lett       Date:  2000-09-15       Impact factor: 2.742

9.  Global tuberculosis incidence and mortality during 1990-2000.

Authors:  P J Dolin; M C Raviglione; A Kochi
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

Review 10.  The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis.

Authors:  H G Wiker; M Harboe
Journal:  Microbiol Rev       Date:  1992-12
View more
  7 in total

Review 1.  Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?

Authors:  Juan I Moliva; Joanne Turner; Jordi B Torrelles
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

2.  Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice.

Authors:  Jiu ling Wang; Ya qing Qie; Bing dong Zhu; Hong mei Zhang; Ying Xu; Qing zhong Wang; Jia zhen Chen; Wei Liu; Hong hai Wang
Journal:  Med Microbiol Immunol       Date:  2008-05-20       Impact factor: 3.402

3.  Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis.

Authors:  Liana Tsenova; Ryhor Harbacheuski; Andre L Moreira; Evette Ellison; Wilfried Dalemans; Mark R Alderson; Barun Mathema; Steven G Reed; Yasir A W Skeiky; Gilla Kaplan
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

Review 4.  Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.

Authors:  Yuan-qiang Zheng; Youssef W Naguib; Yixuan Dong; Yan-chun Shi; Shorgan Bou; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2015       Impact factor: 5.217

Review 5.  Manipulation of BCG vaccine: a double-edged sword.

Authors:  V K Singh; R Srivastava; B S Srivastava
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-25       Impact factor: 3.267

6.  New Recombinant Mycobacterium bovis BCG Expression Vectors: Improving Genetic Control over Mycobacterial Promoters.

Authors:  Alex I Kanno; Cibelly Goulart; Henrique K Rofatto; Sergio C Oliveira; Luciana C C Leite; Johnjoe McFadden
Journal:  Appl Environ Microbiol       Date:  2016-04-04       Impact factor: 4.792

7.  Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung.

Authors:  Ruchi Jain; Bappaditya Dey; Neeraj Dhar; Vivek Rao; Ramandeep Singh; Umesh D Gupta; V M Katoch; V D Ramanathan; Anil K Tyagi
Journal:  PLoS One       Date:  2008-12-04       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.